Collegium Pharmaceutical, Inc.
COLL
$36.06
$1.263.62%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -1.87% | 11.36% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1.87% | 11.36% | |||
| Cost of Revenue | 13.84% | -2.39% | |||
| Gross Profit | -3.68% | 13.20% | |||
| SG&A Expenses | -2.96% | -9.84% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.74% | -5.11% | |||
| Operating Income | -7.45% | 77.17% | |||
| Income Before Tax | -33.15% | 155.13% | |||
| Income Tax Expenses | 1.21% | 136.59% | |||
| Earnings from Continuing Operations | -46.16% | 162.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -46.16% | 162.93% | |||
| EBIT | -7.45% | 77.17% | |||
| EBITDA | -4.12% | 30.71% | |||
| EPS Basic | -46.30% | 164.93% | |||
| Normalized Basic EPS | -4.50% | 147.48% | |||
| EPS Diluted | -45.10% | 143.33% | |||
| Normalized Diluted EPS | -5.78% | 143.32% | |||
| Average Basic Shares Outstanding | 0.26% | -0.75% | |||
| Average Diluted Shares Outstanding | 1.61% | 0.93% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||